Literature DB >> 19915197

Using the PCL-R to help estimate the validity of two self-report measures of psychopathy with offenders.

Norman G Poythress1, Scott O Lilienfeld, Jennifer L Skeem, Kevin S Douglas, John F Edens, Monica Epstein, Christopher J Patrick.   

Abstract

Two self-report measures of psychopathy, Levenson's Primary and Secondary Psychopathy scales (LPSP) and the Psychopathic Personality Inventory (PPI), were administered to a large sample of 1,603 offenders. The most widely researched measure of criminal psychopathy, the Hare Psychopathy Checklist-Revised (PCL-R), served as a provisional referent for estimating the construct validity of these self-report measures with offenders. Compared with the LPSP, the PPI displayed higher zero-order correlations with the PCL-R, better convergent and discriminant validity, and more consistent incremental utility in predicting PCL-R scores. Furthermore, using a variant of Westen and Rosenthal's approach to evaluating the construct validity of a new measure, compared with the LPSP, the PPI's pattern of associations with measures of 35 external criterion variables was more similar to the pattern observed for the PCL-R. Results generally provide stronger support for the validity of the PPI than the LPSP in offender populations using the PCL-R as a provisional benchmark, particularly for assessing interpersonal and affective features of psychopathy.

Entities:  

Mesh:

Year:  2009        PMID: 19915197     DOI: 10.1177/1073191109351715

Source DB:  PubMed          Journal:  Assessment        ISSN: 1073-1911


  24 in total

1.  Are fearless dominance traits superfluous in operationalizing psychopathy? Incremental validity and sex differences.

Authors:  Brett Murphy; Scott Lilienfeld; Jennifer Skeem; John F Edens
Journal:  Psychol Assess       Date:  2016-02-11

2.  The Relation Between the Two Factors of Psychopathy and Intimate Partner Aggression.

Authors:  Susan Iyican; Julia Babcock
Journal:  J Aggress Maltreat Trauma       Date:  2017-08-30

3.  The effects of sertraline on psychopathic traits.

Authors:  Boadie W Dunlop; Jared A DeFife; Lauren Marx; Steven J Garlow; Charles B Nemeroff; Scott O Lilienfeld
Journal:  Int Clin Psychopharmacol       Date:  2011-11       Impact factor: 1.659

4.  Psychopathy in Bulgaria: The cross-cultural generalizability of the Hare Psychopathy Checklist.

Authors:  Michael J Wilson; Carolyn Abramowitz; Georgi Vasilev; Kiril Bozgunov; Jasmin Vassileva
Journal:  J Psychopathol Behav Assess       Date:  2014-09-01

5.  Psychopathy factor interactions and co-occurring psychopathology: Does measurement approach matter?

Authors:  Elizabeth Hunt; Marina A Bornovalova; Eva R Kimonis; Scott O Lilienfeld; Norman G Poythress
Journal:  Psychol Assess       Date:  2015-01-12

6.  Development and validation of Triarchic construct scales from the psychopathic personality inventory.

Authors:  Jason R Hall; Laura E Drislane; Christopher J Patrick; Mario Morano; Scott O Lilienfeld; Norman G Poythress
Journal:  Psychol Assess       Date:  2014-01-20

7.  The relationship between genetic and environmental influences on resilience and on common internalizing and externalizing psychiatric disorders.

Authors:  Ananda B Amstadter; Hermine H Maes; Christina M Sheerin; John M Myers; Kenneth S Kendler
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2015-12-21       Impact factor: 4.328

8.  Psychopathic personality traits and environmental contexts: Differential correlates, gender differences, and genetic mediation.

Authors:  Brian M Hicks; Marie D Carlson; Daniel M Blonigen; Christopher J Patrick; William G Iacono; Matt Mgue
Journal:  Personal Disord       Date:  2011-08-29

9.  Response monitoring and adjustment: differential relations with psychopathic traits.

Authors:  Konrad Bresin; M Sima Finy; Jenessa Sprague; Edelyn Verona
Journal:  J Abnorm Psychol       Date:  2014-06-16

10.  Egocentric Perceptions of the Environment in Primary, but not Secondary, Psychopathy.

Authors:  Konrad Bresin; Ryan L Boyd; Scott Ode; Michael D Robinson
Journal:  Cognit Ther Res       Date:  2013-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.